Emcure Pharmaceuticals (EMCURE) Q2 24/25 earnings summary

Executive summary

• Achieved consolidated revenue of ₹20,019.84 million for Q2FY25, up 20.4% year-over-year and 10.3% sequentially, with strong growth in both domestic and international markets.

• Profit after tax for the quarter was ₹2,015.49 million, a 38.2% increase year-over-year, with PAT margins at 10.1%.

• EBITDA for the quarter reached ₹4,171 million, up 26.1% year-over-year, with EBITDA margins at 20.8%.

• International business sales grew 25% year-over-year, led by a 51% increase in the Canadian business and 29% in the Rest of World segment.

• Domestic business sales rose 15.4% year-over-year, supported by the Sanofi distribution agreement.

Financial highlights

• Revenue from operations for Q2FY25 was ₹20,019.84 million, compared to ₹16,630.89 million in Q2FY24.

• Gross profit for the quarter was ₹1,213 crore, with gross profit margins at 60.6%.

• EBITDA stood at ₹417 crore, up from ₹330 crore in Q2FY24.

• Profit before tax was ₹2,734.10 million, up from ₹1,980.25 million in Q2FY24.

• Earnings per share (basic and diluted) for the quarter were ₹10.33, compared to ₹7.70 in Q2FY24.

Outlook and guidance

• Management aims to enhance margins by leveraging operating efficiencies and driving growth through new product launches and market share gains in both Indian and international markets.

• Focus remains on integrating recent acquisitions and partnerships to derive revenue and operational synergies.